Krabbe Christiaan A, Pruim Jan, Dijkstra Pieter U, Balink Hans, van der Laan Bernard F, de Visscher Jan G, Roodenburg Jan L
Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, The Netherlands.
J Nucl Med. 2009 Dec;50(12):1940-7. doi: 10.2967/jnumed.109.065300. Epub 2009 Nov 12.
The purpose of this study was to evaluate the role and timing of serial (18)F-FDG PET scans as routine surveillance for detecting early locoregional recurrence, distant metastases, and second primary tumors in patients treated for advanced squamous cell carcinoma (SCC) in the oral cavity or oropharynx during the first year after completion of their curative treatment.
Forty-eight consecutive patients with SCC in the oral cavity or oropharynx were included after completing their initial therapy with curative intent. Prospective follow-up of the participants was 2-fold: regular follow-up (history and physical examination) and serial (18)F-FDG PET scans. Patients underwent standard follow-up and (18)F-FDG PET at 3, 6, 9, and 12 mo after initial treatment. Findings were validated by histopathology or 18 mo of clinical follow-up and imaging after initial treatment.
Incidence of recurrences and second primary tumors was 27% and 10%, respectively. (18)F-FDG PET was significantly (P = 0.035) more often in agreement with the gold standard than was regular follow-up. (18)F-FDG PET showed a sensitivity, specificity, positive predictive value, and negative predictive value of 100%, 43%, 51%, and 100%, respectively. For regular follow-up, these values were 0%, 60%, 0%, and 50%, respectively. (18)F-FDG PET accounted for a change in diagnostics or treatment in 63% of the patients and regular follow-up in 25% of the patients. Sensitivity and specificity of (18)F-FDG PET were both irrespective of timing of (18)F-FDG PET. For the 3- and 6-mo posttherapy results combined, (18)F-FDG PET detected malignancy in 16 of the 18 patients.
(18)F-FDG PET is a suitable routine posttreatment surveillance tool in oral and oropharyngeal SCC patients and detects malignancy before clinical suggestion by the regular follow-up arises. The best timing of a systematic (18)F-FDG PET scan is between 3 and 6 mo after treatment.
本研究的目的是评估连续进行的(18)F-FDG PET扫描作为常规监测手段,在口腔或口咽高级别鳞状细胞癌(SCC)患者根治性治疗完成后的第一年,用于检测早期局部区域复发、远处转移和第二原发性肿瘤的作用及时机。
48例口腔或口咽SCC患者在完成根治性初始治疗后被纳入研究。对参与者进行前瞻性随访,分为两方面:常规随访(病史和体格检查)以及连续的(18)F-FDG PET扫描。患者在初始治疗后的3、6、9和12个月接受标准随访和(18)F-FDG PET检查。检查结果通过组织病理学或初始治疗后18个月的临床随访及影像学检查进行验证。
复发和第二原发性肿瘤的发生率分别为27%和10%。(18)F-FDG PET与金标准的一致性显著高于常规随访(P = 0.035)。(18)F-FDG PET的敏感性、特异性、阳性预测值和阴性预测值分别为100%、43%、51%和100%。对于常规随访,这些值分别为0%、60%、0%和50%。(18)F-FDG PET导致63%的患者诊断或治疗发生改变,常规随访导致25%的患者发生改变。(18)F-FDG PET的敏感性和特异性均与(18)F-FDG PET的检查时机无关。对于治疗后3个月和6个月的结果合并分析,(18)F-FDG PET在18例患者中的16例检测到恶性病变。
(18)F-FDG PET是口腔和口咽SCC患者合适的常规治疗后监测工具,并且在常规随访出现临床提示之前就能检测到恶性病变。系统性(18)F-FDG PET扫描的最佳时机是治疗后3至6个月。